Stopped producing Covishield in Dec 2021: SII after AstraZeneca recall
UK-based drug major AstraZeneca's decision to withdraw its Covid-19 vaccine globally, days after admitting to side effects,..
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.
UK-based drug major AstraZeneca's decision to withdraw its Covid-19 vaccine globally, days after admitting to side effects,..
Watch as Akhilesh Yadav addresses the crowd in Mainpuri, Uttar Pradesh, discussing key issues including unemployment, Covishield..